PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients
Study Details
Study Description
Brief Summary
At present, prophylactic cranial irradiation (PCI) is part of standard care for patients with limited-stage small cell lung cancer (SCLC) who have achieved good response after definitive thoracic radiotherapy and chemotherapy. However, the value of PCI is being challenged in the era when MRI examination of brain has been popularized.
The goal of this clinical study is to compare PCI and regular brain MRI follow-up (control arm) and regular brain MRI follow-up alone (study arm) in patients with limited-stage SCLC who have received definitive radiotherapy and chemotherapy and acheived complete remission (CR) of tumor.
The main questions to answer are:
-
Whether the 2-year brain metastasis-free survival rate of the study group is not inferior to that of the control group.
-
The difference of 2-year overall survival rate between the control group and the study group.
-
Whether the patients in the study group have better overall quality of life than those in the control group.
Participants will randomly receive either PCI and regular brain MRI follow-up or regular brain MRI follow-up alone.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Control arm Patients who are randomized to control arm are those who have achieved complete remission of tumor after definitive radio-chemotherapy and will receive PCI and regular brain MRI follow-up. |
Radiation: Prophylactic cranial irradiation
Prophylactic cranial irradiation (PCI) is actually a habitual statement. It is a technique used to eliminate tiny metastatic lesions that have already existed in the brain, but can not be found by brain MRI and other inspection methods.
Radiation: Thoracic radiotherapy
Thoracic radiotherapy is a local treatment of tumors located in the chest using ionizing radiation.
Drug: Chemotherapy
Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
|
| Experimental: Study arm Patients who are randomized to study arm are those who have achieved complete remission of tumor after definitive radio-chemotherapy and will receive regular brain MRI follow-up alone. |
Radiation: Thoracic radiotherapy
Thoracic radiotherapy is a local treatment of tumors located in the chest using ionizing radiation.
Drug: Chemotherapy
Chemotherapy is the abbreviation of chemical drug therapy. It is a treatment method that uses chemical drugs to prevent the proliferation, invasion and metastasis of cancer cells, and finally kill cancer cells.
|
Outcome Measures
Primary Outcome Measures
- 2-year brain metastasis-free survival estimated with kaplan-Meier method [Up to 2 years]
To test with a one-sided significance of 5% whether for the treatment of limited-stage SCLC patients, brain MRI follow-up alone is non-inferior in terms of 2-year brain metastasis-free survival compared to PCI and brain MRI follow-up. Participants were monitored for up to 2 years. The brain metastasis-free survival time is defined as the time between the date of the first treatment until the date of first documented diagnosis of brain metastasis or the date of death from any cause.
Secondary Outcome Measures
- 2-year overall survival estimated with kaplan-Meier method [Up to 2 years]
To compare 2-year overall survival between patients who receive brain MRI follow-up alone and those who receive both PCI and brain MRI follow-up, with kaplan-Meier estimates. Participants were monitored for up to 2 years. The overall survival time is defined as the time between the date of the first treatment until the date of death from any cause.
- Intra-cranial progressive patterns [Up to 2 years]
To compare the intra-cranial progressive patterns between patients who receive brain MRI follow-up alone and those who receive both PCI and brain MRI follow-up within 2 years. Intra-cranial progression is evaluated via the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. In this study, Intra-cranial progressive disease is defined as the new lesions developed in the brain.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically/cytologically proven diagnosis of SCLC.
-
Age ≥ 18 years.
-
Karnofsky performance status ( KPS) ≥80.
-
The limited-stage is defined as the tumor confined to one side of the chest, including ipsilateral hilar, bilateral mediastinum, and bilateral supraclavicular lymph nodes. (The definition of metastatic lymph nodes is that the short diameter ≥ 1cm or PET-CT shows increased metabolism with SUV≥2.5, or proved by mediastinoscopy/EBUS/TBNA biopsy. The thickness of pleural effusion on chest CT is less than 1cm (unless cytology proves to be malignant pleural effusion). According to 8th AJCC/UICC TNM staging system, it is the I-IIIC without intrapulmonary metastasis.
-
Patients who have received definitive chest radiotherapy and chemotherapy and achieved complete remission of tumor within 4-6 weeks after the end of radio-chemotherapy (in accordance with the Response Evaluation Criteria in Solid Tumors v.1.1 including enhanced CT scan of chest and abdomen, enhanced brain MRI, bone scan and tumor markers).
-
Good follow-up compliance;
-
Fully understand this study, and voluntarily sign the informed consent form.
Exclusion Criteria:
-
Patients with a history of malignant tumors (past or concurrent) within 5 years, excluding papillary thyroid cancer, non-malignant melanoma skin cancer and cervical carcinoma in situ.
-
Patients who have received radical surgery (excluding biopsy).
-
Patients with psychiatric history, pregnancy and lactation.
-
Uncontrolled diabetes, hypertension, severe active infection.
-
Patients with chronic diseases of central nervous system.
-
Patients with contraindications of brain MRI examination.
-
Other situations deemed unsuitable by the doctor in charge.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Zhejiang Cancer Hospital
- Sun Yat-sen University
- First Affiliated Hospital, Sun Yat-Sen University
Investigators
- Principal Investigator: Xiao Hu, MD, PhD, Zhejiang Cancer Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PCI+MRI vs. MRI